Michael Kim, MD, Discusses Study on Mutant p53 and Oncogenic KRAS in Pancreatic Cancer

Video

The MD Anderson expert discussed the main takeaway from the data published during the virtual AACR Annual Meeting, while looking forward to what comes next with these genetic drivers.

Michael Kim, MD, from The University of Texas MD Anderson Cancer Center, spoke with CancerNetwork about the main takeaways and potential action regarding mutant p53 and oncogenic KRAS in pancreatic cancer to be taken from his research presented at the virtual AACR Annual Meeting.

Transcription:

Targeting genetic drivers of cancer has proven to be very successful. For example, in melanoma and in certain types of hematopoietic malignancies (leukemias and GI stromal tumors), we know that targeting genetic drivers can be very effective. But we don't have any therapies that target oncogenic KRAS that's prevalent in pancreatic cancer. And we have no therapies that target mutant p53. Since these are the heart and brain of pancreatic cancer, we need to find novel ways to target these. One way is to identify how they work together and attack that cooperative signaling node somewhat like dividing and conquering.

So, if we can disentangle or decouple oncogenic KRAS from mutant p53, our hope is that we can prevent or highly disrupt metastasis. And then we can use other targeted, or potentially immunotherapies, to kill the actual tumor cells. So, it's really kind of identifying CREB1 is the link between oncogenic KRAS effectors and mutant p53 gain of function. And then using other drugs in our armamentarium to target the tumor cells themselves.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content